Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
05 janv. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist
Global Obesity Drugs and Delivery Platforms Market Research Report 2023: GLP-1-based Drugs, Along With Injector and Nanomaterial Delivery Platforms, Drive Transformational Industry Growth
05 janv. 2024 06h08 HE
|
Research and Markets
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering. In this study, the...
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
02 janv. 2024 02h00 HE
|
Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure
14 déc. 2023 05h45 HE
|
Fractyl Health, Inc.
Fractyl Health Announces New Pooled Analysis From Revita Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance without Gain
Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting
11 déc. 2023 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health presented preclinical findings from its Rejuva® gene therapy platform at the WCIRD23 Annual Meeting.
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
04 déc. 2023 02h30 HE
|
Zealand Pharma
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and...
ACADEMY OF NUTRITION AND DIETETICS URGES CONGRESS: PASS BILL TO INCREASE ACCESS TO NUTRITION CARE
15 nov. 2023 09h00 HE
|
Academy of Nutrition and Dietetics
Chicago, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics supports and advocates for expanded access to medical nutrition therapy and additional coverage for more chronic...
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
25 oct. 2023 06h50 HE
|
ZyVersa Therapeutics
Obesity exacerbates scarring of the heart through ASC-driven inflammasome activation in the heart leading to damaging inflammation.
Digital Therapeutics Market Is Projected to Gain $22.60 Billion By 2031, Growing at a 19.4% CAGR: Allied Market Research
23 oct. 2023 22h00 HE
|
Allied Market Research
Wilmington, Delaware, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The global digital therapeutics market size was estimated at $3.84 billion and is projected to gain $22.60 billion in 2031, exhibiting a...
Studies Investigate the Impact of Obesity on Outcomes after the Total Ankle Replacement (TAR) Procedure
17 oct. 2023 16h00 HE
|
American Orthopaedic Foot & Ankle Society (AOFAS)
Rosemont, Ill., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Total Ankle Replacement (TAR), also known as total ankle arthroplasty, is a surgical procedure that foot and ankle orthopaedic surgeons use to treat...